In 2012, another multicenter study (NCT01520870) assessed the efficacy and safety of the multi-kinase dacomitinib in patients with recurrent GBM with EGFR gene amplification and/or EGFRvIII mutation, which was determined by in situ hybridization fluorescent (FISH) and/or PCR respectively in the primary tumor [97]. The gene discussed is EGFR; the disease is glioblastoma.